Trials / Completed
CompletedNCT02101034
PD 0332991 and Cetuximab in Patients With Incurable SCCHN
Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase I/II study is to define the maximum tolerated dose of PD 0332991 given with cetuximab and evaluated the side effects of the combination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cetuximab | |
| DRUG | PD 0332991 |
Timeline
- Start date
- 2014-06-17
- Primary completion
- 2020-06-08
- Completion
- 2023-11-10
- First posted
- 2014-04-01
- Last updated
- 2023-12-21
- Results posted
- 2021-06-11
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02101034. Inclusion in this directory is not an endorsement.